A full-length glycoprotein mRNA vaccine confers complete protection against severe fever with thrombocytopenia syndrome virus, with broad-spectrum protective effects against bandaviruses. [PDF]
Lu J +10 more
europepmc +1 more source
Suppression of Interferon Response and Antiviral Strategies of Bunyaviruses. [PDF]
He Y +6 more
europepmc +1 more source
Research progress on antiviral drugs and vaccines for severe fever with thrombocytopenia syndrome. [PDF]
Chen C +7 more
europepmc +1 more source
N-glycosylation of viral glycoprotein is a novel determinant for the tropism and virulence of highly pathogenic tick-borne bunyaviruses. [PDF]
Shimojima M +8 more
europepmc +1 more source
Advancements in vaccine development and therapeutic approaches for severe fever with Thrombocytopenia Syndrome. [PDF]
Ganbold T +4 more
europepmc +1 more source
Innate immune response against vector-borne bunyavirus infection and viral countermeasures. [PDF]
Li M.
europepmc +1 more source
The emerging tick-borne Yezo virus - current knowledge, challenges, and perspectives. [PDF]
Markarian NM, Abrahamyan L.
europepmc +1 more source
A broadly protective antibody targeting glycoprotein Gn inhibits severe fever with thrombocytopenia syndrome virus infection. [PDF]
Ren X +13 more
europepmc +1 more source
Computer-Selected Antiviral Compounds: Assessing In Vitro Efficacies against Rift Valley Fever Virus. [PDF]
Alkan C, O'Brien T, Kenyon V, Ikegami T.
europepmc +1 more source
Emerging Tick-borne Infections in the Upper Midwest and Northeast United States Among Patients With Suspected Anaplasmosis. [PDF]
Reller ME +3 more
europepmc +1 more source

